POTELIGEO
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTELIGEO (POTELIGEO).
Comprehensive clinical and safety monograph for POTELIGEO (POTELIGEO).
Adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy
Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).
| Metabolism | Mogamulizumab is a monoclonal antibody; metabolism is via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes identified. |
| Excretion | POTELIGEO (mogamulizumab) is a monoclonal antibody, primarily eliminated via intracellular catabolism into amino acids. No quantitative data on renal or biliary excretion; minimal to no excretion as intact antibody in urine or feces. |
| Half-life | Terminal elimination half-life is approximately 17 days (range 11–22 days) at steady state, supporting every-2-week or every-4-week dosing intervals. |
| Protein binding | Approximately 95% bound to plasma proteins, predominantly to immunoglobulins and albumin as a therapeutic monoclonal antibody. |
| Volume of Distribution | Volume of distribution at steady state (Vss) is approximately 5.1 L (range 3.8–6.7 L), indicative of limited extravascular distribution, consistent with a monoclonal antibody primarily confined to vascular and interstitial spaces. |
| Bioavailability | Only intravenous administration; intravenous bioavailability is 100% by definition. |
| Onset of Action | Clinical response (e.g., reduction in circulating Sézary cells) observed as early as 4 weeks after first intravenous infusion; maximal response may require several cycles. |
| Duration of Action | Duration of therapeutic effect continues throughout treatment course; after discontinuation, pharmacodynamic effects (e.g., depletion of CCR4-positive cells) persist for weeks to months, correlating with antibody clearance. |
| Molecular Weight | 144900 |
3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl 30-89 mL/min). Insufficient data for severe renal impairment (CrCl <30 mL/min) or dialysis. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. Insufficient data for Child-Pugh C. Use with caution. |
| Pediatric use | Safety and effectiveness not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Monitor for adverse effects more frequently due to potential age-related renal and hepatic function decline. |
| 1st trimester | No adequate human data; animal studies showed fetal harm. Avoid unless benefit outweighs risk. |
| 2nd trimester | No adequate human data; potential fetal harm. Use only if clearly needed. |
| 3rd trimester | No adequate human data; potential fetal harm. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for POTELIGEO (POTELIGEO).
| Placental transfer | IgG monoclonal antibodies cross placenta; transfer increases as pregnancy progresses, especially in third trimester. |
| Breastfeeding | Not known if excreted in human milk; risk of serious adverse reactions in nursing infants. Discontinue breastfeeding or drug based on importance of drug to mother. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | POTELIGEO (mogamulizumab) is a monoclonal antibody. IgG antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on its mechanism of action (CCR4-directed cytolytic activity), there is potential for fetal harm, including depletion of maternal and fetal T-cell subsets, especially regulatory T cells, which are critical for immune tolerance. Animal studies have not been conducted, but given the pharmacodynamics, use during pregnancy should be avoided unless clearly necessary. First trimester exposure carries theoretical risks of altered immune development; second and third trimester exposure may cause fetal lymphopenia and increased infection risk. |
| Fetal Monitoring | Monitor complete blood counts (CBC) with differential, including lymphocyte counts, before and during therapy. Assess liver function tests (LFTs) and renal function. Monitor for infections, infusion-related reactions, and skin toxicity (e.g., Stevens-Johnson syndrome). Obtain pregnancy test in women of reproductive potential prior to initiation. Fetal monitoring: Consider serial ultrasound for growth assessments if used in pregnancy, though no specific fetal monitoring guidelines exist. |
| Fertility Effects | No human data on fertility effects. In animal studies with an anti-CCR4 antibody, no adverse effects on male or female fertility were observed. However, based on the mechanism, potential for disruption of immune homeostasis and possible effects on reproductive tissues expressing CCR4 cannot be excluded. Women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last dose. |
■ FDA Black Box Warning
WARNING: DERMATOLOGIC TOXICITY. Severe, including fatal, dermatologic adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred. Discontinue for suspected severe cutaneous adverse reactions.
| Serious Effects |
None known
| Precautions | Infusion reactions: Monitor during infusion; interrupt or discontinue based on severity., Dermatologic toxicity: Severe skin reactions including SJS/TEN; discontinue if suspected., Immune-mediated adverse reactions: including pneumonitis, hepatitis, colitis, endocrinopathies, and others., Infections: Fatal infections occurred; monitor for infections and treat promptly., Autoimmune hemolytic anemia: Fatal cases reported., Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected., Hematologic toxicity: Monitor blood counts; severe neutropenia, thrombocytopenia, and anemia reported., Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception. |
| Food/Dietary | No known food interactions. Grapefruit or other CYP inhibitors/inducers are not expected to affect mogamulizumab as it is a monoclonal antibody cleared via proteolysis. No dietary restrictions necessary. |
| Clinical Pearls | Poteligeo (mogamulizumab) is a humanized anti-CCR4 monoclonal antibody used for adult T-cell leukemia-lymphoma (ATLL) and mycosis fungoides (MF)/Sézary syndrome (SS). It depletes CCR4-expressing T cells, including regulatory T cells (Tregs), which may exacerbate graft-versus-host disease (GVHD) after transplant. Monitor for infusion reactions and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome). Dose reduction for creatinine clearance <30 mL/min is not established; avoid in severe renal impairment. Premedicate with antihistamines and acetaminophen. Live vaccines contraindicated during and after treatment. |
| Patient Advice | Poteligeo can cause severe skin reactions; report any rash, blisters, or peeling skin immediately. · You may experience infusion reactions (fever, chills, nausea) during or after infusion; premedication will be given. · Avoid live vaccines (e.g., MMR, varicella) during treatment and for at least 1 year after last dose. · Do not breastfeed while on Poteligeo and for at least 2 months after last dose. · Use effective birth control during treatment and for at least 3 months after last dose. · Notify your doctor if you have a history of organ transplant or are planning a transplant. · Poteligeo can lower your immune system; report signs of infection (fever, cough, sore throat). |
Loading safety data…